An increase in the clinical significance of cutaneous malignant melanoma has paralleled a dramatic increase in the rate of death from this disease. The critical genetic changes associated with the genesis and progression of this disease are only beginning to be identified. This review highlights genetic changes in cutaneous melanoma and discusses the genetics of predisposition, cytogenetics, changes in proto-oncogenes and oncogenes, and evidence for the role of tumor suppressor genes in this malignancy. The viewpoint of this article is that malignant melanoma is a genetic disease.
Get full access to this article
View all access options for this article.
References
1.
VogelsteinB., KinzlerK.W.The multistep nature of cancer. Trends Genet.1993; 9: 138–141.
2.
KraehnG.M., SchartlM., PeterR.U.Human malignant melanoma: a genetic disease?Cancer.1995; 75: 1228–1237.
BaleS.J., DracopoliN.C., TuckerM.A.Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med.1989; 320: 1367–1372.
9.
WalkerG.J., NancarrowD.J., WaltersM.K.Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer.1994; 59: 771–775.
10.
BaleS.J., GreeneM.H., MurrayC.Hereditary malignant melanoma is not linked to the HLA complex on chromosome 6. Int J Cancer.1985; 36: 439–443.
11.
FountainJ.W., BaleS.J., HousmanD.E.Genetics of melanoma. Cancer Surv.1990; 9: 645–671.
12.
ThompsonF.H., EmersonJ., OlsonS.Cytogenetics in 158 patients with regional or disseminated melanoma: subset analysis of near diploid and simple karyotypes. Cancer Genet Cytogenet.1995. In press.
13.
TrentJ.M., ThompsonF.H., MeyskensF.L.Jr. Identification of a recurring translocation site involving chromosome 6 in human malignant melanoma. Cancer Res.1989; 49: 420–423.
14.
TrentJ.M., StanbridgeE.J., McBrideH.L.Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science.1990; 247: 568–571.
15.
YouJ., MieleM.E., DongC.Suppression of human melanoma metastasis by introduction of chromosome 6 may be partially due to inhibition of motility, but not to inhibition of invasion. Biochem Biophys Res Commun.1995; 208: 476–484.
16.
ParmiterA.H., BalabanG., ClarkW.H.Jr. Possible involvement of the chromosome region 10q24–q26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet.1988; 30: 313–317.
17.
TrentJ.M., MeyskensF.L., SalmonS.E.Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med.1990; 322: 1508–1511.
18.
BennettD.C.Genetics, development, and malignancy of melanocytes. Int Rev Cytol.1993; 146: 191–260.
19.
HalabanR.Growth regulation in normal and malignant melanocytes. Recent Results Cancer Res.1993; 128: 133–150.
20.
RodeckU.Growth factor independence and growth regulatory pathways in human melanoma development. Cancer Metastasis Rev.1993; 12: 219–226.
21.
ShihE.M., HerlynM.Role of growth factors and their receptors in the development and progression of melanoma. J Invest Dermatol.1993; 100(Suppl 2): 196S–203S.
22.
KoprowskiH., HerlynM., BalabanG.Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet.1985; 11: 297–302.
23.
WillbrodtJ., AdamD., MalitschekB.Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus. Nature.1989; 341: 415–421.
24.
PerisK., CerroniL., ChimentiS.Proto-oncogene expression in dermal naevi and melanomas. Arch Dermatol Res.1991; 283: 500–505.
25.
ZhangJ., TrentJ.M., MeltzerP.S.Rapid isolation and characterization of amplified DNA by chromosome microdissection: identification of IGF1R amplification in malignant melanoma. Oncogene.1993; 8: 2827–2831.
26.
LinnenbachA.H., HuebnerK., ReddyE.P.Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines. Proc Natl Acad Sci U S A.1988; 85: 74–78.
27.
NataliP.G., NicotraM.R., WinklerA.B.Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer.1992; 52: 197–201.
28.
FleischmanR.A., SaltmanD.L., StastnyV.Deletion of the c-kit protooncogene in the human developmental defect piebald trait. Proc Natl Acad Sci U S A.1991; 88: 10855–10889.
29.
FunasakaY., BoultonT., CobbM.c-kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated kinase but is down regulated in melanomas. Mol Biol Cell.1992; 3: 197–209.
30.
ZakutR., PerlisR., EliyahuS.KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene.1993; 8: 2221–2229.
31.
WeissJ., SchwechheimerK., CaveneeW.K.Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer.1993; 54: 693–699.
32.
AkslenL.A., MrkveO.Expression of p53 protein in cutaneous melanoma. Int J Cancer.1992; 52: 13–16.
33.
SerranoM., HannonG.J., BeachD.A new regulatory motif in cell-cycle control causing specific inhibition of cycline D/CDK4. Nature.1993; 366: 704–707.
